Kiniksa Pharmaceuticals
Price & Volume
Stats
See more52W Range | $18.12-$44.41 |
Market Cap | $2.9B |
Shares Short | 3M |
Financials
See moreRevenue (12 Mos) | $597.9M |
Revenue Growth (YoY) | 61.2% |
Gross Profit (12 Mos) | $315.6M |
Diluted EPS | $0.45 |
News
See moreYahoo Finance • 19 days ago
Exploring High Growth Tech Stocks In The US December 2025
Yahoo Finance • 23 days ago
Why Analysts Favor Kiniksa Pharmaceuticals (KNSA)
Yahoo Finance • 3 months ago
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
Yahoo Finance • 3 months ago
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
About
CEO | Mr. Sanj K. Patel |
CFO | Mr. Mark A. Ragosa C.F.A. |
Address | 23 Old Bond Street, London, United Kingdom, WIS 4PZ |
Sector | Healthcare |
Industry | Drug Manufacturers - Specialty & Generic |
Full-Time Employees | 315 |
